Pfizer raised profit estimates for 2025 thanks to cost cuts, despite falling COVID product revenue and patent expirations.
Sanziana Georgescu
Economy
sursa foto: shutterstock.com
Always see our news on Google
Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
08:44
Rareș Bogdan: “If the Luca Niculescu government were to fall, I believe the president would be forced, on the one hand, by USR, PNL, partly UDMR, and AUR, which would push for snap elections”
08:36
The World Bank is discussing with 30-40 countries the provision of emergency financial assistance amid the energy crisis.
08:18
The death toll from the shipwreck in Djibouti has reached 139, while 84 people are still missing
08:12
PSD decides today how it will support the Luca Niculescu government / The conditions the party has for the designated prime minister
08:04
Zelensky accuses Russia of attacking Ukraine’s energy infrastructure after the ceasefire announced by Trump
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
